Comparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitus

Basit Öğe Kaydı
dc.contributor.authorAydin, Pelin
dc.contributor.authorUzuncakmak, Sevgi Karabulut
dc.contributor.authorTor, Ibrahim Hakki
dc.contributor.authorBilen, Arzu
dc.contributor.authorOzden, Ayse
dc.date.accessioned2024-10-04T18:49:24Z
dc.date.available2024-10-04T18:49:24Z
dc.date.issued2022
dc.departmentBayburt Üniversitesien_US
dc.description.abstractObjective: In the present study, the relationship between a poor prognosis and adropin levels in diabetic patients with coronavirus disease 2019 was investigated by measuring serum adropin levels and levels of D-dimer, C-reactive protein, and ferritin, which are considered prognostic factors for coronavirus disease 2019. Materials and Methods: Hundred volunteer participants treated in the Erzurum Regional Training and Research Hospital were included in this study. Serum adropin levels were measured by enzyme-linked immunosorbent assay. The relationship between serum adropin level and C-reactive protein, ferritin, and D-dimer levels was analyzed by correlation analysis. Results: The participants' serum adropin levels differed between the groups (P=.0007). The control group had the highest adropin levels among groups. The lowest adropin levels were in the COVID + diabetes mellitus group. Adropin levels of diabetes mellitus, COVID, and diabetes mellitus + COVID groups were significantly decreased when compared to the control (P<.05). There was a significant negative correlation between adropin and C-reactive protein, D-dimer, and ferritin. Conclusion: Adropin can be used as an auxiliary biomarker, a prognostic factor in the early management of coronavirus disease 2019 patients with diabetes mellitus. We think that our study will guide future studies conducted in this field.en_US
dc.identifier.doi10.5152/eurasianjmed.2022.22128
dc.identifier.endpage201en_US
dc.identifier.issn1308-8742
dc.identifier.issue2en_US
dc.identifier.pmid35703530en_US
dc.identifier.scopus2-s2.0-85131783012en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage197en_US
dc.identifier.trdizinid530194en_US
dc.identifier.urihttps://doi.org/10.5152/eurasianjmed.2022.22128
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/530194
dc.identifier.urihttp://hdl.handle.net/20.500.12403/3106
dc.identifier.volume54en_US
dc.identifier.wosWOS:000810387100016en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAtaturk Univen_US
dc.relation.ispartofEurasian Journal of Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdropinen_US
dc.subjectCOVID-19en_US
dc.subjectDMen_US
dc.subjectd-dimeren_US
dc.subjectCRPen_US
dc.titleComparison of Serum Adropin Levels in Patients with Diabetes Mellitus, COVID-19, and COVID-19 with Diabetes Mellitusen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu